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Summary Ecto-5'-nucleotidase (ecto-S'-NT) is a phosphatidylinositol anchored membrane structure recently
defined as the lymphocyte differentiation antigen CD73. Using CD73 (IE9.28.1) monoclonal antibody, normal
mammary gland and breast carcinoma were immunohistochemically investigated for ecto-5'-NT expression. In
normal breast epithelium, CD73 was differentially expressed in lobular, ductal and myoepithelial cells and was
most frequently detected in the myoepithelial compartment. The glandular stroma contained fibrocytes, a
subset of which was also CD73-positive. Among 102 unselected breast carcinoma primary lesions, only 9
contained CD73-positive tumour cells, whereas in 95 cases, stromal fibroblasts and fibrocytes showed variable
degrees of CD73 expression. The extent of stromal CD73 expression correlated positively with the estrogen
receptor (ER) status of the tumour (P<0.038). We conclude that ecto-5'-NT-expression reflects a still
unknown state of activity of normal breast epithelium which is lost in the majority of carcinomas derived
therefrom. It may also be indicative of some functional activity of stromal fibroblasts which is significantly
enhanced in ER-positive carcinomas.
Ecto-5'-nucleotidase (ecto-5'-NT) corresponds to the recently
defined lymphocyte differentiation antigen CD73 (Thompson
et al., 1990). Ecto-5'-NT is a novel maturation marker for
both T and B cells since the enzyme activity in peripheral
blood T cells is approximately 10-fold higher than in thy-
mocytes (Edwards et al., 1979) and since in adult peripheral
B cells it is five- to six-fold higher than in foetal spleen or
cord blood B cells (Thompson et al., 1986; Bastian et al.,
1984). Ecto-5'-NT is encoded on chromosome 6 (Boyle et al.,
1988) and is a cell membrane associated enzyme of 69 kDa.
In liver, placenta, and in lymphocytes, a substantial fraction
of ecto-5'-NT activity can be released from membranes by
the action of a phosphatidylinositol-specific phospholipase C,
indicating the lack of a membrane-spanning segment and
anchoring to the cell surface via a glycosyl phosphatidyl-
inositol (GPI) moiety (Low & Finean, 1978; Thompson et
al., 1987, 1990; Bailyes et al., 1990; Misumi et al., 1990).
Monoclonal antibodies to a number of GPI-anchored lym-
phocyte differentiation antigens cause activation and pro-
liferation (reviewed in Low, 1989) and recent experiments by
Robinson et al. (1989) suggest that GPI anchors may be
uniquely suited for transmembrane signal transduction.
Immunohistological investigations showed expression of
CD73 antigen in the mantle-zone B-cells and follicular dend-
ritic reticulum cells of the lymphoid tissue, in the endothelial
cells of capillaries and venules, in the basal layer of non-
keratinising squamous epithelium and in the transitional cell
type mucosa of the upper respiratory and urinary tract
(Thompson et al., 1990). In normal mammary gland CD73
antigen expression was found to be variable (Moller &
Mielke, 1989).
This study aims at a more detailed analysis of CD73
expression among the different cell types constituting the
mammary gland and at an investigation of possible changes
in neoplastic transformation.
Materials and methods
Tissue
A series of 102 unselected primary malignant breast tumours
was collected in the course of a clinical-pathological study on
mammary carcinoma. This series of frozen tumours was
stored at - 70'C. From each specimen four serial frozen
sections of about I cm2 and a thickness of4 to 6 gm were cut
and air-dried overnight, fixed in acetone for 10 min at room
temperature and immediately immunostained. Nearly half of
the examined mammarian carcinomas contained non-neo-
plastic glandular remnants, either normal or exhibiting var-
ious aspects of fibrocystic mastopathy. In addition, represen-
tative tissue specimen of ten normal non lactating mammary
glands were examined.
Clinico-pathological data ofthepatients
Clinico-pathological characteristics of the 102 mammary car-
cinomas are shown in Table I. The hormone receptor status
was biochemically determined by the dextran-coated charcoal
(DCC) assay (Raam et al., 1982). The threshold for positivity
was 20 fmol mg-' protein. Menopausal status was taken
from anamnestic data; for statistical analysis perimenopausal
patients were regarded as 'not further defined'.
Histological tumour grading was classified according to
Bloom and Richardson (Bloom & Richardson, 1957). Clini-
cal tumour typing and staging were performed according to
the recommendations of the Internation Union Against
Cancer (Histological Typing of Breast Tumours, 1981; TNM
Classification of Malignant Tumours, 1987).
Reagents
The monoclonal CD73 antibodies (1E9.28.1) (IgG3) and
7G2.2.11 (IgG2a) both recognising the plasma membrane
bound form of ecto-5'-NT, were raised and characterised by
one of us (Thompson et al., 1989); AD2 (IgGl) was raised
and characterised by M. Cooper, Birmingham, AL, USA,
and was distributed to the participants of the 4th Interna-
tional Workshop and Conference on Leucocyte
Differentiation Antigens, Vienna, 1989. A polyclonal
biotinylated sheep antibody to mouse Ig (reactive with all
mouse isotypes) and a streptavidin-biotinylated peroxidase
complex, both obtained from Amersham (High Wycombe,
UK) served as the detection system for the mouse mono-
clonal primary antibodies.
Stainingprocedures
CD73 mAb IE9.28.1, 7G2.2.1 1, and AD2 were diluted to
approximately 150jig ml-' in phosphate-buffered saline
(PBS) containing 0.1% bovine serum albumine. The secon-
dary anti-mouse Ig antibody was diluted 1:50, and the
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Table I Structure of the cohort of 102 breast carcinoma
patients
Clinical features
Age of the patients at
time of operation:
Mean age (years) ( s.d.)
Youngest patient
Oldest patient
Hormone receptor status
of the carcinomas:
Estrogen receptors
Progesterone receptors
Menopausal status:
Premenopausal
Postmenopausal
Perimenopausal
56.5 (± 13.1)
27
91
Positive
Negative
Unclear
Positive
Negative
Unclear
57
39
6
55
41
6
20
54
28
Pathological features
Histological tumour type:
Ductal invasive
Lobular invasive
Ductal carcinoma in situ
Mucinous
Unclassified
Histological tumour grading:
Grade I; I/II
Grade II
Grade 11/111; III
Unclassified
Quantity of tumour stroma*:
Fibroblast content of
tumour stroma*:
Tumour diameter:
Mean (cm) ( ± s.d.)
Tumour < 2 cm
2 cm <Tumour<5 cm
Tumour > 5 cm
Unclear
Tumour staging:
Stage I
Stage II
Stage III
Stage IV
Unclear
*Semiquantitative evaluation,
reactive breast, 'high' meaning
content, respectively.
74
19
1
4
3
3
63
36
8
High 54
Low 48
High 32
Low 70
3.2 (± 2.58)
22
43
20
17
7
37
35
1
22
'low' meaning comparable to
superior to normal quantity or
Controls
Positive controls for the specificity of IE9.28.1 (IgG3) were
carried out by applying two different CD73 monoclonal
antibodies of different Ig isotypes on frozen tissue sections of
hyperplastic tonsillitis and normal mammary gland: 7G2.2.11
(IgG2a) and AD2 (IgGI); the antibodies yielded identical
staining patterns. Negative controls were performed in each
case without the primary antibody; no staining was observed
except for scattered granulocytes due to a staining caused by
endogenous peroxidase which was not blocked for the benefit
of optimal antigenicity.
Evaluation
Evaluation of CD73 antigen expression was carried out
independently by two observers; final consensus was obtained
using a double-microscope. The stroma quantity and its
fibroblast content was determined for each carcinoma as
'high' or 'low'. For the evaluation of the amount of stained
cells a simple semiquantitative score was set up (see footnotes
of Table II): a tumour was considered negative, '-', when
all tumour cells were clearly negative. A mixed pattern of
ecto-5'-NT positive and negative tumour cells was symbolised
'-/+'. A tumour was considered positive, '+', when all
cells of each tissue component expressed CD73 antigen. For
statistical analysis, the Chi2 test and the Fisher's exact test
were applied.
Results
Normal and reactive mammary gland
In normal non lactating breast tissue CD73 expression of
cellular constituents was very variable, irrespective of the
menopausal status. The ductal and acinar epithelium was
predominantly CD73-negative, however, in some glands there
were mostly small foci where these cells were faintly or
strongly CD73-positive (Figure 1); in addition the antigen
could be detected inconsistently in myoepithelial cells and
rarely in fibrocytes of the glandular stroma. There was no
obvious association of epithelial CD73 expression and duct-
ectasia or apocrine metaplasia or cyst formation, nor was it
correlated with sclerosing adenosis. This CD73 distribution
pattern could also be observed in non-neoplastic glandular
remnants of the tumour tissues examined: lobular and ductal
epithelium of the non-neoplastic tissue was negative in 80%
of the carcinomas examined. It was CD73-positive in two out
of 49 cases (4%). In 8/49 (16%) carcinomas the normal
epithelium was mixed, negative and faintly CD73-positive.
The myoepithelial compartment of the non-neoplastic tissue
Table II Ecto-5'-NT-expression in cellular tissue components of 102
breast carcinomas examined
Tissue compartment Number of cases -* -/+ +
Normal gland epithelium 49 39 8 2
Myoepithelial cells 49 28 2 19
fumour cells 102 93 4 5
Stromal fibroblasts of 102 7 26 69
tumour stroma
*Semiquantitative score - all cells negative; -/+, mixed pattern
with CD73-positive and -negative cells; +, all cells positive
(irrespective of staining intensity).
streptavidin-peroxidase complex was applied at a dilution of
1:100. All dilutions and washing steps were carried out in
PBS. Tissue was incubated 1 h at room temperature with the
primary antibody and 30 min with the second- and third-step
reagents. Using 3-amino-9-ethylcarbazole (AEC) as the
chromogen (0.4 mgml-' in 0.1M of acetate buffer pH 5.0
with 5% dimethylformamide (DMF) and 0.01% H202 for
10 min), the peroxidase reaction resulted in an intense red
precipitate. The sections were counterstained with Harris'
haematoxylin and mounted with glycerol gelatin.
Nu1
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Figure I Normal mammary gland. Monoclonal antibody CD73
(IE.28.1) detects ecto-5'-NT in lobular epithelium and in peri-
glandular and periductal fibrocytes. In this microarea ductal
epithelium and myoepithelial cells are CD73-negative (indirect
immunoperoxidase technique, using aminoethylcarbazole as the
chromogen and a faint haematoxylin counterstain; same techni-
que for Figures 2-5), x 120.116 K.H. KRUGER et al.
Figure 2 This lobular invasive carcinoma (grade II-III) which Figure 5 This ductal invasive carcinoma (grade II-Ill) which
was biochemically oestrogen receptor negative contains very few was biochemically oestrogen receptor positive contains high
CD73-positive stromal fibrocytes/-blasts and does not express amounts of strongly CD73-positive stromal fibroblasts but does
CD73 within the neoplastic population. By contrast, the myo- by itself not express ecto-5'-NT, x 120.
epithelial cells of ductal remnants contain high amounts of ecto-
5'-NT. x 120.
Figure 3 This ductal invasive carcinoma (grade II) which was
oestrogen receptor positive is CD73-negative but contains a mod-
erate number of CD73-positive fibrocytes within the tumour
stroma, x 120.
Figure 4 This ductal invasive carcinoma (grade II), which was
oestrogen receptor negative expresses low amounts of CD73 as
do the stromal fibroblasts, x 120.
was CD73-negative in 28 out of 49 cases (57%). In two out
of 49 cases (4%) it was mixed, negative and weakly positive.
Nineteen out of 49 cases (39%) contained strongly positive
myoepithelial cells.
Breast carcinoma
Investigating the CD73 antigen expression of the 102 breast
carcinomas, 93 out of 102 (91%) were completely negative
(Figure 2), four out of 102 (4%) contained both CD73-
negative and -positive tumour cells and five out of 102 (5%)
were weakly but entirely CD73-positive (Figure 4). Distorted
and/or destroyed glandular remnants within the carcinomas
were occasionally observed to express CD73 (e.g., Figure 2);
however, the extent of CD73-positivity of this non-neoplastic
compartment could not be exactly determined since it was
not sufficiently well discernible as such from the carcinoma
itself. Differences in the intensity of staining of myoepithelial
cells in non-cancerous breast as compared to reactive myo-
epithelial remnants within cancerous lesions were not ob-
vious.
The mode of CD73 expression in fibroblasts of the tumour
stroma tended to be opposite to that of neoplastic cells.
Seven out of 102 carcinomas (7%) had CD73-negative
fibroblasts of the tumour stroma, whereas in 26 out of 102
carcinomas (25%), the fibroblast population was mixed with
small numbers of negative and a majority of strongly CD73-
positive cells (Figure 3; Figure 5). In 69 out of 102 tumours
(68%) the fibroblast compartment was completely and
strongly CD73-positive.
Statistical analysis revealed no correlation between the
mode of CD73 expression of the glandular and myoepithelial
compartment in non-neoplastic breast on the one hand and
age or menopausal status on the other hand. The mode of
CD73 expression within the carcinoma cell compartment was
neither correlated with the patients' age or menopausal status
nor with the hormone receptor status, histological tumour
type, grade of differentiation or postoperative staging of the
tumours. However, a significant positive correlation was
found between CD73 antigen expression in the stromal
fibroblasts and the biochemically determined ER status of
the tumours (P<0.038).
Discussion
We have shown that the normal and fibrocystic state of the
non-lactating mammarian gland is characterised by a variable
CD73 expression in lobular and ductal epithelium and in the
myoepithelial compartment. Reactive gland which could be
detected in the vicinity of half of the tumour tissues
examined showed a roughly corresponding pattern of CD73-
positivity: ductal and acinar epithelial cells were positive in
20% of the cases; (subsets of) myoepithelial cells contained
the antigen in 43%.
As compared to their normal counterparts, i.e., lobular
and ductal epithelium, carcinoma cells expressed the antigen
even more infrequently: only 9% of the cases were complete-
ly CD73-positive or contained variable amounts of CD73-
positive tumour cells. This might be due to a loss of the
capacity to express ecto-5'-NT upon stimuli yet to be defined.
In contrast to the rare expression of CD73 antigen in tumour
cells, the cells of the tumour stroma were completely CD73-
positive in 68% and predominantly positive in 26% of the
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cases. The fibroblasts of the tumour stroma were completely
CD73-negative in only 7% of carcinomas.
The functional role of ecto-5'-NT (CD73) in cellular com-
ponents of normal and neoplastic breast tissue has not yet
been defined. Ecto-5'-NT catalyses the extracellular dephos-
phorylation of purine and pyrimidine ribo- and deoxyribo-
nucleotide monophosphates to the corresponding ribo- and
deoxyribo-nucleosides (Naito & Lowenstein, 1981). These
compounds then may be transported inside the cell and
reconverted to nucleotides via the purine salvage pathway.
Thereby the enzyme can regulate the uptake of purines by
converting non-transportable 5'-nucleotides (mainly adeno-
sine monophosphates) into a transportable form (Shah et al.,
1986; Thompson, 1985).
In lymphocytes, it was shown that the catalytic activity of
ecto-5'-NT can provide the total purine requirements of
mitogen-stimulated human T cells and rapidly dividing hu-
man B lymphoblastoid cells (Thompson, 1985). Anti-5'-nuc-
leotidase-IgG completely depressed cell proliferation, show-
ing clearly that this is the only enzyme on the lymphocyte
surface that is capable of degrading extracellular nucleotides
(Andree et al., 1987). Whether or not ecto-5'-NT may salvage
extracellular nucleotides in breast tissue, however, is still
unknown.
Ecto-5'-NT is thought to be a maturation marker for both
T and B cells because of its significant higher enzyme activity
in the peripheral lymphocytes than in immature precursor
cells (Thompson et al., 1989). Inhibition of ecto-5'-NT activ-
ity suppressed the proliferative and cytotoxic response of
alloreactive T lymphocytes. These studies suggest a critical
role of this cell surface enzyme in the functional maturation
of both T and B lymphocytes (Massaia et al., 1988). In
addition, it was reported that substantial T cell proliferation
can be induced when T lymphocytes are cultured for 3 days
in the presence of CD73 monoclonal antibody 1E9.28.1 plus
phorbol myristate acetate (PMA) and F(ab')2 goat anti-
mouse IgG as a cross-linking reagent (Thompson, 1990)
which indicates a possible agonistic effect of the monoclonal
antibody to its receptor. Extending this knowledge of the
functional role of ecto-5'-NT in lymphocytes to breast tissue
cells, we conclude that CD73 antigen expression could be a
sign of their maturation state and/or susceptibility to activa-
tion.
A number of tumour-cell produced substances are known
to induce or act directly on the adjacent stroma cells (Dvor-
ak, 1986; Martinez-Hernandez, 1988). Tumours secrete sub-
stances such as tumour angiogenesis factor (Folkman, 1985),
which are capable of acting on vascular structures. The ex-
tracellular matrix secreted by human breast cancer cells has
been shown to be mitogenic for fibroblasts (Kao et al., 1984).
Transforming growth factors (TGF alpha, TGF beta) are
able to cause reversible phenotypic transformation of fibro-
blasts (Hsuan, 1989). In hormone dependent MCF-7 breast
cancer cells, oestrogen-induced growth factors were identified
that may have a role in growth control and might act as
oestrogen-induced 'second messengers' in oestrogen-respon-
sive growth of human breast cancer (Dickson et al., 1986;
Knabbe et al., 1987). Our statistical analysis revealed an
interdependence between the oestrogen receptor status of
breast carcinomas and the ecto-5'-NT-expression of the adja-
cent stromal fibroblasts. Whether any of these effects of
oestrogen-induced growth factors are mediated via CD73 will
now have to be investigated.
This study was supported by a grant of the Tumorzentrum Hei-
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